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ABSTRACT
Treatment of non-small cell lung cancer (NSCLC) is based on
histological analysis and molecular profiling of targetable driver
oncogenes. Therapeutic responses are further defined by the
landscape of passenger mutations, or loss of tumor suppressor
genes. We report here a thorough study to address the physiological
role of the putative lung cancer tumor suppressor EPH receptor A3
(EPHA3), a gene that is frequently mutated in human lung
adenocarcinomas. Our data shows that homozygous or
heterozygous loss of EphA3 does not alter the progression of murine
adenocarcinomas that result from Kras mutation or loss of Trp53, and
we detected negligible postnatal expression of EphA3 in adult wild-
type lungs. Yet, EphA3 was expressed in the distal mesenchyme of
developing mouse lungs, neighboring the epithelial expression of its
Efna1 ligand; this is consistent with the known roles of EPH receptors
in embryonic development. However, the partial loss of EphA3 leads
only to subtle changes in epithelial Nkx2-1, endothelial Cd31 and
mesenchymal Fgf10 RNA expression levels, and no macroscopic
phenotypic effects on lung epithelial branching, mesenchymal cell
proliferation, or abundance and localization of CD31-positive
endothelia. The lack of a discernible lung phenotype in EphA3-null
mice might indicate lack of an overt role for EPHA3 in the murine
lung, or imply functional redundancy between EPHA receptors. Our
study shows how biological complexity can challenge in vivo
functional validation of mutations identified in sequencing efforts, and
provides an incentive for the design of knock-in or conditional models
to assign the role of EPHA3 mutation during lung tumorigenesis.
KEY WORDS: EPHA3, EPH receptor A3, GEMM, Adenocarcinoma,
Lung morphogenesis
INTRODUCTION
Lung cancer is a leading cause of cancer-related deaths worldwide.
More than 85% of all lung cancers are classified as non-small cell
lung cancer (NSCLC), which is further sub-classified as
adenocarcinoma (ADC; ~50%) and squamous cell carcinoma (SCC;
~40%) (Chen et al., 2014). In recent years, excellent progress in
molecular profiling of NSCLC has identified stratified patient groups
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that benefit from targeted therapies (Oxnard et al., 2013). Specifically,
erlotinib or gefitinib are prescribed to patients that carry mutations in
epidermal growth factor receptor (EGFR), and crizotinib to carriers of
anaplastic lymphoma kinase (ALK) gene rearrangements. However,
despite an increase in progression-free survival, the overall survival
benefit of such tyrosine kinase inhibitors remains marginal, and
profound intra- and inter-tumor genetic heterogeneity confounds
effective long-term responses (de Bruin et al., 2014).
Next-generation sequencing of lung cancer patient tumors has
identified numerous putative new cancer drivers, including EPH (also
defined as erythropoietin-producing hepatocellular) receptor A3
(EPHA3), which is mutated in 6–16% of lung ADC samples (Cancer
Genome Atlas Research Network, 2014; Ding et al., 2008; Imielinski
et al., 2012). The EPH receptors make up the largest family of receptor
tyrosine kinases (RTKs) and, together with their ephrin ligands, they
control a variety of biological processes. They are classified into two
subclasses based on sequence homologies, namely EPHA and EPHB
receptors and their ephrin-A and ephrin-B ligands. Interaction between
the EPH receptors and their ligands at cell-cell contacts triggers
signaling into both the receptor- and ligand-expressing cell. Such
bidirectional signaling induces changes in the actin cytoskeleton, cell-
substrate adhesion, intercellular junctions and cell shape, impinging
on cell movement and tissue patterning (Pasquale, 2010). Context-
dependent cellular responses are finely tuned by the abundance and
type of receptor-ligand pairs expressed in neighboring cells, leading to
specialized cell functions known to control synaptic plasticity, insulin
secretion, epithelial homeostasis and inflammatory immune responses
(Gucciardo et al., 2014; Pasquale, 2010).
The expression pattern of EphA3 in mammalian tissues suggests
that there is a role for EPHA3 in neuronal development and
formation of mesoderm-derived tissues (Kilpatrick et al., 1996;
Kudo et al., 2005; Yue et al., 1999). However, in contrast to
predictions made based on its expression in the developing medial
motor column, constitutive loss of murine EphA3 does not lead to
abnormal motor axon topography (Vaidya et al., 2003). Instead, 75%
of the null mice die at birth owing to cardiac abnormalities caused
by defective endothelial-to-mesenchymal transition, a specific form
of mesenchymal conversion that generates progenitors of the
atrioventricular valves (Stephen et al., 2007).
With respect to its putative role in tumorigenesis, previous studies
have indicated that EPHA3 can signal both in a kinase-dependent
and kinase-independent manner, inducing both tumor-promoting and
tumor-suppressing effects (Boyd et al., 2014). For example, in
glioblastoma multiforme, EPHA3 is highly expressed in
undifferentiated mesenchymal cells where it has been shown to
confer a kinase-independent oncogenic role through regulating
mitogen-activated protein kinase (MAPK) signaling (Day et al.,
2013). A tumor-suppressive role of EPHA3, in particular for lung
cancer, is supported by the reduction in receptor activity conferred
by the point mutations found in cancers, and ligand- and EPHA3-
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dependent apoptosis of tumor and stroma cells upon receptor agonist
treatment, suggesting that wild-type EPHA3 has anti-tumorigenic
properties (Lahtela et al., 2013; Lisabeth et al., 2012; Vail et al.,
2014; Zhuang et al., 2012). Furthermore, the finding that senescence
elicited by acute EPHA3 loss is rescued by loss of p16INK4A
(encoded by Cdkn2a) or p53 (encoded by Trp53) suggests that
EPHA3 mutation might promote tumorigenesis only in the absence
of senescence-inducing pathways (Lahtela et al., 2013). Given the
opposing outcomes of aberrant EPH-ephrin signaling, careful
dissection of the tissue and cell-context-specific EPH receptor
functions requires studies that utilize valid in vivo model systems.
Genetically engineered mouse models (GEMMs) are the most
widely applied and functionally validated in vivo models of human
lung cancer, in particular to validate gene cooperation concomitant
with conditional expression of the oncogenic Kras gene (Jackson et
al., 2001; Jackson et al., 2005; Ji et al., 2007; Schramek et al., 2011;
Snyder et al., 2013). Importantly, murine clinical studies have shown
that oncogenic signaling in Kras-driven GEMMs is crucially defined
by the cooperating tumor suppressor, with loss of liver kinase B1
(Lkb1) conferring different therapeutic responses compared with loss
of Trp53 (Chen et al., 2012). Despite convincing data suggesting a
tumor suppressor role for EPHA3 during lung tumor progression, thus
far no studies have addressed its in vivo functional role. We therefore
decided to utilize the EphA3-null mice to test the effect of constitutive
loss of EphA3 on lung ADC progression driven by mutant Kras (LSL-
KrasG12D/+) (Jackson et al., 2001) and loss of Trp53 (p53fl/fl) (Marino
et al., 2000), hereafter referred to as Kras and p53. Our data shows that
the constitutive loss of EphA3 does not alter the progression of murine
ADC in either of these models. Moreover, despite clear evidence for
EphA3 expression in the developing lung, similar to key regulators of
morphogenesis known to regulate lung tumorigenesis (Clark et al.,
2001; Snyder et al., 2013; Yin et al., 2013), an analysis of selected
EphA family receptors shows that EphA3 has a non-unique or minimal
function during lung morphogenesis. Our study thus provides an
incentive for rational design of novel GEMMs to unequivocally assign
the role of EPHA3 during lung tumorigenesis in vivo.
RESULTS
Constitutive loss of EphA3 does not accelerate mutant
Kras- or p53-loss-driven lung tumorigenesis
To test the hypothesis that EPHA3 acts as a lung tumor suppressor,
we used a previously described constitutive EphA3-null mouse
model (Stephen et al., 2007; Vaidya et al., 2003). EphA3-null mice
did not show any marks of reduced survival during a 1-year follow-
up period, indicating that mere EphA3 loss does not drive
tumorigenesis. We therefore assessed whether EphA3 loss could
accelerate tumorigenesis induced by conditional alleles known to
initiate lung ADC, following a classic multi-allele paradigm. These
‘first hit’ conditional models comprised mutant Kras (Jackson et al.,
2001) and loss of p53 (Marino et al., 2000), which are also 
common drivers of human disease found in at 17% and 35% of
ADCs, respectively (COSMIC, 2014; http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic/). In lung ADC, EPHA3 mutations
show a statistically significant tendency towards co-occurrence with
mutations in TP53 (P<0.01) and occasional, but not statistically
significant, co-occurrence with KRAS mutations (supplementary
material Fig. S1A). We established cohorts of 8-16 mice for each
genetic combination (homozygous p53 or heterozygous Kras with
wild-type EphA3, or homozygous or heterozygous null EphA3).
Lung-specific deletion of conditional alleles was achieved through
intranasal inhalation of adenoviral Cre recombinase (CMV-AdCre),
affording transduction of bronchiolar and alveolar progenitor cells,
to initiate carcinoma progression. The infection efficacy was
confirmed with a dual fluorescence mT/mG Cre-reporter strain that
monitors in vivo integration efficiency through activating a Cre-
dependent switch from membrane-tagged Tomato to GFP
(supplementary material Fig. S1B) (Muzumdar et al., 2007). Tumor
burden analysis at 19 weeks after CMV-AdCre infection showed
that constitutive loss of EphA3 did not alter mutant Kras-driven lung
ADC progression (Fig. 1A,B; supplementary material Fig. S1C).
Similar to previous findings in murine Kras lung cancer studies
(Jackson et al., 2001), all EphA3 genotype cohorts displayed distinct
types of progressive lesions, including epithelial hyperplasia,
adenomas and ADCs. In addition, we detected previously described
profound inflammatory responses as infiltrations of macrophages
and neutrophils (supplementary material Fig. S1C) (Ji et al., 2006).
Furthermore, analysis of histopathology and NKX2-1 and tumor
protein 63 (p63) biomarker expression to respectively depict ADC
and SCC tissue, showed that constitutive absence of EphA3 did not
alter the tumor histology (Fig. 1C). We further found that the loss of
EphA3 did not alter the latency of p53-loss-driven ADCs (Fig. 1D).
Thus, the constitutive absence of EPHA3 expression does not
accelerate mutant Kras- or p53-loss-driven lung tumorigenesis.
Mesenchymal expression of EphA3 suggests that it has a
functional role during lung development
As previous studies have indicated a role for EphA3 in embryonic
development, we undertook a detailed expression analysis of EphA3
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TRANSLATIONAL IMPACT
Clinical issue
Lung cancer is the leading cause of cancer-related deaths worldwide.
Molecular profiling to identify targetable driver mutations is increasingly
being applied in the clinic, and can stratify patient groups. However,
pronounced patient- and tumor-specific lung tumor heterogeneity
confounds long-term or predictable clinical responses. Hence, validation
of de novo driver mutations using appropriate in vivo model systems is
important. The EPH receptor A3 (EPHA3) tyrosine kinase is among the
most frequently mutated cancer genes in human lung adenocarcinomas.
However, we still lack mouse genetic studies to unequivocally validate
its previously assigned putative tumor suppressor function in human lung
adenocarcinomas.
Results
Here, the authors test the applicability of EphA3-null mice to address the
functional importance of EPHA3 in mutant Kras- or p53-loss-driven
mouse lung adenocarcinomas. The study shows that constitutive loss of
EphA3 does not alter mutant Kras-driven lung adenocarcinoma
progression, nor the histopathology or latency of p53-loss-driven
adenocarcinomas. Moreover, the study identifies EPHA3 as a receptor
that is expressed in embryonic lung mesenchyme and describes subtle
lung morphogenesis gene expression changes in EphA3 heterozygous
embryonic lungs. No gross phenotypic changes in morphogenesis-
related functions are detected in EphA3 heterozygous or null embryonic
lungs.
Implications and future directions
This study highlights the importance of creating appropriate model
systems to study the in vivo functional relevance of putative cancer
drivers, such as EPHA3. Our studies utilizing Epha3-null mice fail to
validate a putative tumor suppressor function for EPHA3 in human lung
cancer. Furthermore, the overlapping expression pattern of EPH
receptors detected in the developing mouse embryonic lung might imply
functional redundancy. Therefore this study provides an incentive to the
design of sophisticated, possibly tissue-specific, knock-in or conditional
mouse models using genome-editing tools such as the prokaryotic type
II CRISPR/Cas-system to elucidate the role of EPHA3 mutations during
















in the developing mouse lung. Both RNA in situ hybridization
(Fig. 2A) and immunohistochemical staining (Fig. 2B) demonstrated
expression of EphA3 in the distal mesenchyme of the embryonic
lung. The specificity of the EPHA3 antibody was confirmed by
absence of detectable immunohistochemical staining in EphA3-null
embryos (Fig. 2A,B), as well as a decreased signal in hTERT-RPE1
cells treated with EPHA3 small interfering RNA (siRNA)
(supplementary material Fig. S1D). Expression of EPHA3 in the
developing lung was detected during embryonic ages E11.5 to E15.5
(Fig. 2B,C), which falls into the pseudoglandular (E9.5-E16.5) stage
of murine lung development. During this stage, the newly generated
primary lung buds develop into a complex branched tree-like
structure ending in thousands of epithelial terminal tubules,
accompanied by continued mesenchymal growth around the
growing epithelia (Morrisey and Hogan, 2010). Based on this
mesenchymal expression in the developing mouse lungs we
hypothesized that EPHA3 might function during the
pseudoglandular stage of lung development.
Expression of multiple EPH receptors in the developing
mouse lung suggests involvement in lung morphogenesis
We next asked how mRNA expression of EphA3 during murine lung
morphogenesis might correlate with or impact on mRNA expression
of other EphA receptors in epithelial and mesenchymal cells at
E11.5, E13.5 and E15.5 of lung development (Fig. 3A). At E11.5
we performed quantitative PCR (q-PCR) expression analysis on
both proximal and distal epithelium and mesenchyme. At E13.5 and
E15.5, the analysis was restricted to the distal regions,
approximating the terminal epithelial buds and their surrounding
mesenchyme. We found that among the studied EphA receptors,
only expression of EphA3 was restricted to the developing lung
mesenchyme, and closely overlapped with expression of known
mesenchymal Fgf10 and endothelial Cd31 (also known as Pecam1)
genes (Fig. 3B; supplementary material Fig. S2A). EphA7
expression was detected both in the mesenchyme and epithelia, and
was the only other EphA receptor co-expressed with EphA3 in the
mesenchyme (Fig. 3B). Importantly, we did not detect any
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Fig. 1. Constitutive loss of EphA3 does not alter mutant Kras-driven or p53 loss-induced lung ADCs. (A) Representative sections (stained with H&E)
depicting the tumor burden in Kras;EphA3+/+, Kras;EphA3+/− and Kras;EphA3−/− lungs 19 weeks post CMV-AdCre infection (3.3×107 PFUs) show no difference
between the genotypes. Black arrows indicate the site of magnified images. (B) Average tumor-to-lung area at 19 weeks after CMV-AdCre infection of the
Kras;EphA3+/+, Kras;EphA3+/− and Kras;EphA3−/− lungs. Two separate lung regions were used for tumor burden analysis. n=9 for Kras;EphA3+/+, n=16 for
Kras;EphA3+/− and n=8 for Kras;EphA3−/−. Results are mean±s.d. (C) Immunohistochemical analysis of the ADC marker NKX2-1 and squamous cell carcinoma
marker p63 in Kras;EphA3+/+, Kras;EphA3+/− and Kras;EphA3−/− tumors, indicating positive nuclear staining for NKX2-1 and negative for p63. (D) Survival
curves of n=7 for p53;EphA3+/+, n=11 for p53;EphA3+/− and n=13 for p53;EphA3−/− mice treated with CMV-AdCre (3.3×108 pfu). Mice were monitored for 15
months, during which one out of seven p53;EphA3+/+ and two out of 13 p53;EphA3−/− mice died due to CMV-AdCre-induced ADC formation. NS, P>0.05

















compensatory changes in EphA7 expression levels in the
heterozygous or homozygous EphA3-null embryonic lungs
(supplementary material Fig. S2B). EphA2 and EphA4 were found
to be expressed mainly in epithelial cells, whereas expression of
EphA1 and EphA5 was absent in both tissue compartments
(Fig. 3B). These results correlate with in situ hybridization data
described by the Allen Institute for Brain Science, with the
exception of EphA1, for which moderate expression was detected in
murine lung epithelia (Allen Institute for Brain Science, 2013). We
further confirmed the epithelial expression of the known ligand of
EPHA3, ephrin-A1 (encoded by Efna1), at E11.5, E13.3 and E15.5
(Fig. 3B; supplementary material Fig. S2C). Finally, postnatal
murine lung expression analysis revealed very low EphA3 and
EphA7 expression levels when compared to that of the embryonic
mesenchyme (E13.5), whereas EphA2 and EphA4 expression were
higher in the adult tissue (supplementary material Fig. S3A). Taken
together, our data identifies EphA3 as a mesenchymal EPH receptor
and suggests that its ligand ephrin-A1 is expressed in the adjacent
branching epithelia. Furthermore, the low expression of EphA3 in
adult tissue suggests that EPHA3 is absent or has a minimal role in
postnatal lung homeostasis.
EphA3 heterozygosity is associated with altered expression
of branching morphogenesis and vasculogenesis genes
Next, we investigated whether constitutive loss of EphA3 affected
the mRNA expression of known lung morphogenesis genes. A
targeted q-PCR analysis of known regulators of lung morphogenesis
identified a small but significant increase in the expression of Nkx2-
1 in heterozygous EphA3 embryonic epithelium at E13.5 when
compared with wild-type tissue (Fig. 3C). Furthermore, similar
expression increases were detected in endothelial Cd31 and
mesenchymal Fgf10 (Fig. 3C). In contrast, analysis at E15.5 failed
to show statistically significant expression differences for these three
genes (supplementary material Fig. S3B) suggesting that any role
for EphA3 during pseudoglandular lung development is transitory.
Taken together, the partial loss of EphA3 appears to induce subtle
and transitory alterations in epithelial Nkx2-1, endothelial Cd31 and
mesenchymal Fgf10 mRNA expression, suggesting that EPHA3
function might modulate lung morphogenesis.
Constitutive loss of EphA3 does not overtly affect murine
lung morphogenesis
We next asked whether the constitutive loss of EphA3 was directly
associated with altered lung branching morphogenesis. We first
performed a quantitative analysis of lung branch end-points at E13.5
by E-cadherin whole-mount immunohistochemistry staining and
optical projection tomography (OPT) to visualize branching
epithelia. The number of terminal branches was found to be identical
in EphA3 heterozygous (average 113) and null embryonic lungs
(average 110) when compared to age-matched littermate controls
(average 108) (Fig. 4A,B). Additional qualitative analysis using E-
cadherin-stained E11.5 and E15.5 whole-mount lungs further
confirmed that EPHA3 does not overtly affect lung branching
morphogenesis (supplementary material Fig. S3C). Next, we
assessed whether loss of EphA3 was associated with an alteration in
distal mesenchymal cell proliferation. Analysis of in vivo BrdU
incorporation showed that there was no statistically significant
increase in the percentage of mesenchymal S phase cells in EphA3
heterozygous (36%) or EphA3-null (26%) lungs at E13.5 when
compared to littermate controls (26%) (Fig. 4C). Finally, we studied
whether the pulmonary vasculature formation was altered by loss of
EphA3 by analyzing CD31 expression at E13.5. In both EphA3-null
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Fig. 2. Mesenchymal expression of EphA3 during lung development. (A) In situ hybridization analysis of EphA3 expression in embryonic mouse lungs at
E14.5, showing its distal mesenchymal expression. (B) Immunohistochemical analysis of EPHA3 protein in embryonic mouse lungs at E11.5, E13.5 and E15.5
confirms the distal mesenchymal expression. (C) Quantitative PCR analysis of epithelial and mesenchymal mRNA expression of EphA3 at E11.5, E13.5 and
















and heterozygous lungs, the number of CD31-positive endothelial
cells at E13.5 was identical to that of the controls (Fig. 4D). Taken
together, the data presented here show that constitutive loss of
EphA3 does not overtly alter murine lung morphogenesis.
DISCUSSION
The functional validation of de novo mutations identified in lung
cancer sequencing efforts is a prerequisite for the development of
novel targeted therapies. EPHA3 is among the most frequently
mutated RTKs in human lung ADCs, and has been assigned a
candidate tumor suppressor role based on its mutation spectrum and
findings from in vitro and in vivo studies (Lahtela et al., 2013;
Lisabeth et al., 2012; Vail et al., 2014; Zhuang et al., 2012).
However, the actual role of EPHA3 during lung tumor progression
has not been investigated nor validated using GEMMs. Our previous
findings linked loss of EPHA3 to p53 activation (Lahtela et al.,
2013), and EPHA3 and TP53 point mutations display statistically
significant co-occurrence in lung ADC (supplementary material
Fig. S1A). We hence asked whether the absence of EphA3 enhanced
the incidence of p53-loss-driven lung cancer progression.
Additionally, we asked whether loss of EphA3 accelerated lung
ADC progression caused by the commonly mutated Kras oncogene.
We here show that the constitutive absence of EPHA3 does not
affect tumor progression and histopathology of both p53-loss- and
mutant Kras-driven lung ADCs. Thus, EphA3-null mice fail to
validate a putative tumor suppressor function for EPHA3 in human
lung cancer, perhaps owing to functional redundancy between
murine EphA receptors expressed in adult lungs. Interestingly,
sequencing of murine small cell lung cancer (SCLC) tumors
initiated by loss of p53 and retinoblastoma 1 (Rb1) revealed that
there were recurrent somatically acquired EphA5 and EphA7
mutations (McFadden et al., 2014). This means that there is a strong
case for further lung tumorigenesis studies to study the role of EphA
receptor biology in GEMMs, and in particular the physiological role
of EphA5 and EphA7.
Re-activation of EPH-receptor–ephrin pathways, generally known
to contribute to cell sorting and tissue patterning in embryonic
development, has been causally linked with tumorigenesis
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Fig. 3. Embryonic lung gene expression analysis of selected EphA family and morphogenesis genes. (A) Schematic workflow describing the mRNA
expression analysis of E11.5, E13.5 and E15.5 embryonic lung epithelium and mesenchyme. (B) Average mRNA expression levels of selected EphA family
receptors and Efna1 ligand. Expression of epithelial Nkx2-1 and Cdh1, mesenchymal Fgf10 and endothelial Cd31, correlates with their known expression
patterns. E11.5, n=2, E13.5 and E15.5, n=4. The inset shows the distribution of the samples within the observed expression values. (C) Comparative mRNA
expression analysis of EphA3+/+, EphA3+/− and EphA3−/− dissected embryos at E13.5 shows a minor but statistically significant difference between EphA3+/+and

















(Nievergall et al., 2012). Moreover, expression of key regulators of
embryonic lung morphogenesis, Fgf9 and Fgf10 (Colvin et al.,
2001; Min et al., 1998; White et al., 2006), has been shown to
trigger ADC and adenoma progression, respectively (Clark et al.,
2001; Yin et al., 2013). Thus far, of all EphA receptors and ligands,
only a role of the ephrin-B2 ligand has been described during lung
development. Specifically, ephrin-B2 has been shown to regulate
alveolar epithelial and endothelial viability and vascular growth in
hyperoxic rats (Vadivel et al., 2012), as well as pulmonary
compliance in mice (Bennett et al., 2013). Our current data shows
that EphA3 is expressed specifically in the mesenchymal distal lung
tips during the pseudoglandular stage of branching morphogenesis,
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Fig. 4. Constitutive loss of EphA3 does not alter morphogenesis of murine lungs. (A) Representative E-cadherin whole-mount images of EphA3+/+,
EphA3+/− and EphA3−/− embryonic lungs at E13.5 and corresponding images from branch end-point analyses, indicating end points in green. (B) Mean±s.d. of
the branch end-point number from EphA3+/+, EphA3+/− and EphA3−/− lungs at E13.5 shows no difference between EphA3+/− and EphA3−/− embryonic lungs
when compared to EphA3+/+ lungs; n=6 in all three genotypes. (C) Representative images from BrdU and nuclear Hoechst immunohistochemical staining in
EphA3+/+, EphA3+/− and EphA3−/− embryonic lungs at E13.5. Segmentation of representative images was performed to calculate distal-mesenchyme-specific
BrdU proliferation analysis. Mean±s.d. values of the amount of BrdU-positive cells relative to the total number of Hoechst-stained nuclei shows no difference
between EphA3+/+, EphA3+/− and EphA3−/− embryonic lungs at E13.5. n=3 for EphA3+/+ and EphA3−/−; n=1 for EphA3+/−. Analysis was done on two separate
regions of the embryonic lungs. NS, P<0.05 (Student’s t-test). (D) Representative images of CD31-positive endothelial cells of EphA3+/+, EphA3+/− and

















albeit at low levels. However, whereas for example the removal of
Fgf10 results in dramatic defects in lung organogenesis (Min et al.,
1998), partial loss of EphA3 appears to induce only subtle increases
in epithelial Nkx2-1, endothelial Cd31 and mesenchymal Fgf10
mRNA expression levels. Furthermore, no macroscopic phenotypic
effect on lung epithelial branching, mesenchymal cell proliferation,
or abundance and localization of CD31-positive endothelia was
measured. This lack of a discernible phenotype might indicate: (1)
lack of an overt, or a different, role for EPHA3 in the murine lung;
(2) functional redundancy between lung-expressed EphA receptors;
or (3) a partial penetrance of the EphA3-null genotype. 
Of the selected EphA receptors, we found that only EphA7 was
co-expressed with EphA3 in the lung mesenchyme. Interestingly, a
recent study has suggested that there is functional compensation of
EphA3 loss by EphA7 co-expression during palate development, as
compound homozygous mutation of EphA3 and EphA4 failed to
cause defective midfacial development (Agrawal et al., 2014).
Furthermore, a truncated form of EPHA7 has been reported to act
as a tumor suppressor in follicular lymphoma (Oricchio et al., 2011),
and it would thus be interesting to study its potential role in lung
tumor suppression in conjunction with EphA3 loss of function.
Taken together, we report that loss of EphA3 does not lead to
measurable effects on lung ADC progression, nor lung
morphogenesis, in the applied constitutive null GEMM. Importantly,
we cannot exclude the possibility that other EphA receptors co-
expressed in the (developing) lung, most notably EphA7, can
compensate for the decreased expression of EphA3. Our findings
therefore provide an incentive to perform a rational design of tissue-
specific knock-in or conditional mouse models to unequivocally
assign the role of EPHA3 mutation or loss of expression, possibly in
the context of compound EPHA-ephrin network mutations, on lung
tumorigenesis in vivo. In this respect, the ability to apply prokaryotic
type II CRISPR/Cas genome editing tools to introduce somatic
germline mutations in mice (Sanchez-Rivera et al., 2014; Yang et al.,
2013) provides promise for future tumor modeling approaches.
MATERIALS AND METHODS
Mouse cohorts and tissue preparation
Animal studies were carried out in accordance with guidelines from the
Finnish National Board of Animal Experimentation, and were approved by
the Experimental Animal Committee of the University of Helsinki and the
State Provincial Office of Southern Finland (License number ESAVI-2010-
04855/Ym-23). EphA3-null mice lacking a genetic region encompassing the
first exon of EphA3 were previously described (Stephen et al., 2007; Vaidya
et al., 2003). Mice carrying a conditional mutant allele of Kras (LSL-
KrasG12D/+) (Jackson et al., 2001) or a loss-of-function allele of Trp53
(p53fl/fl) (Marino et al., 2000) were purchased from The Jackson Laboratory.
EphA3-null mice were bred with Kras and p53 mice to generate the study
cohorts, and were maintained on a mixed genetic background using
littermates as controls. Multiple litters of the same age were used to provide
sufficient numbers of each genotype. Lung tumorigenesis was initiated by
infecting mice at 6-10 weeks of age with 3.3×107 (Kras) or with 3.3×108
(p53) plaque-forming units (PFUs) of recombinant adenovirus expressing
the Cre recombinase (University of Turku, Finland), using intranasal
instillation as described elsewhere (Jackson et al., 2001). Viruses were
administered in a Biosafety Level 2+ room according to the guidelines of
the Finnish Board for Gene Technology. Lungs from mice were fixed in 4%
formaldehyde, and all lobes were embedded in paraffin.
Tumor burden analysis and survival curves
Lungs from Kras;EphA3−/−, Kras;EphA3+/− and Kras;EphA3+/+ mice at 19
weeks post infection were processed as described above and paraffin sections
(4 μm) were cut from two distinct zones (middle and bottom) of each paraffin
block, thus generating two sections each representing the whole lung surface
area, which were stained with H&E. Whole slide scans of the H&E-stained
lung sections were acquired with a Pannoramic 250 3DHISTECH
(3DHISTECH Kft., Budapest, Hungary) digital slide scanner with a 20×
objective. Whole slide images were assessed for tumor burden using the
Tissue studio image analysis solution of the Definiens Developer XD 64 2.1
software (Definiens, Munich, Germany). The histopathology of the lesions
and inflammatory infiltrations were diagnosed by an expert pathologist. Long-
term follow up of infected p53;EphA3−/−, p53;EphA3+/− and p53;EphA3+/+
mice was performed until 15 months, and mice were killed when showing
labored breathing. Sections (4 μm) were cut from two distinct zones (middle
and bottom) of each paraffin block, stained with H&E and qualitatively
analyzed for tumor appearance. Kaplan-Meier survival curves were generated
using Prism (GraphPad Software, Inc., San Diego, CA).
Histology and immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded sections (4 μm).
Sections were dehydrated and antigenic epitopes were exposed by heating in
10-mM citrate buffer (pH 6.0) or by incubation in 0.05% trypsin at +37°C.
Sections were incubated with the following antibodies: anti-NKX2-1 (Abcam,
Cambridge, UK); anti-p63 (Abcam, Cambridge, UK); anti-EPHA3
(Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA); anti-CD31 (Becton,
Dickinson and Company, Franklin Lakes, NJ); anti-GFP (polyclonal rabbit
serum 8 mg/ml, generated in house). Primary antibody staining was detected
using Bright vision poly-horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (ImmunoLogic, Duiven, The Netherlands), HRP-conjugated goat
anti-rat IgG (Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA) and
3,3′-diaminobenzidine (DAB) (Immunologic, Duiven, The Netherlands) or
Alexa-Fluor-488-conjugated anti-rabbit IgG (Life Technologies/Thermo
Fisher Scientific Inc., Waltham, MA). Sections were counterstained with
Mayers hemalum solution (Millipore, Billerica, MA) or Hoechst 33342 dye
(Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA). Image acquisition
was performed either using a Nikon 90i Eclipse microscope (Nikon
Instruments Europe BV, The Netherlands) and DS-Fi2 5 MP camera, or a
Pannoramic 250 3DHISTECH (3DHISTECH Kft., Budapest, Hungary)
digital slide scanner with a 20× objective.
In situ hybridization
Radioactive in situ hybridization was performed on paraffin sections
according to the standard protocols using probes labeled with 35[S]-UTP.
Dark-field images were inverted, linearly thresholded and combined with
brightfield images in Adobe Photoshop CS6 (Adobe Systems Software,
Dublin, Ireland). The mouse EphA3 probe was an 817-bp fragment
(nucleotides 658-1474) inserted into pGEM-3Zf- vector. The mouse Efna1
probe was a 402-bp fragment (nucleotides 20-421) inserted into pGEM-3Zf-
vector. The Fgf10 probe was a 584-bp fragment (nucleotides 11-579)
inserted into Bluescript KSII+ vector.
BrdU proliferation assay
A timed pregnant mouse was injected with 5-bromo-2′-deoxyuridine (BrdU)
(Sigma, St Louis, MO) and killed 4 hours later to harvest embryos at
embryonic age of 13.5. Embryos were fixed in 4% formaldehyde and
embedded in paraffin. Sections (4 μm) were cut from two distinct zones of
the embryonic lungs. BrdU-positive cells were detected using anti-BrdU
antibody (Cell Signaling Technology, Danvers, MA) and counterstained with
Hoechst 33342 using standard immunohistochemical methods. Image
acquisition was performed with a Nikon 90i Eclipse microscope (Nikon
Instruments Europe BV, The Netherlands) and DS-Fi2 5 MP camera. Image
analysis was done using NIS-Elements AR 4.2 software (Nikon Instruments
Europe BV, The Netherlands).
Preparation of embryonic lung tissue
Embryonic lung dissection and epithelial and mesenchymal cell separation
was performed as previously described (del Moral and Warburton, 2010),
with small modifications. Briefly, pregnant mice were killed to harvest
embryos at E11.5, E13.5 and E15.5 by CO2 administration. Collected
embryos were dissected under a stereoscopic microscope in a glass Petri
dish immersed in PBS. Isolated lungs were then transferred to 24-well plates
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containing CO2-independent medium (Gibco by Life Technologies/Thermo
Fisher Scientific Inc., Waltham, MA). Epithelial and mesenchymal tissues
were separated by treating with 10 mg/ml collagenase (collagenase from
Clostridium histolyticum, Sigma) in CO2-independent medium at 37°C for
20 minutes. Enzymatic degradation was stopped by adding CO2-independent
medium supplemented with 5 U/ml RNase-free DNase (RQ1 RNase free
DNase, M6101, Promega, WI). Depending on the embryonic age,
mesenchymal and epithelial cells from one to five embryos were used to
reach high enough RNA yields.
Quantitative PCR analysis
Normal adult lung tissue was homogenized using a Precellys homogenization
kit (Bertin Technologies, Montigny-le-Bretonneux, France). Total RNA was
extracted using NucleoSpin RNA II kit (MACHEREY-NAGEL, Düren,
Germany) and quantified using NanoDrop 1000 (Thermo Fisher Scientific
Inc.). Complementary DNA (cDNA) was synthesized from the extracted RNA
using a High-capacity cDNA reverse transcription kit (Applied Biosystems by
Life Technologies/Thermo Fisher Scientific Inc.). The q-PCR amplification
was performed using iQ™ SYBR® Green Supermix (Bio-Rad, Hercules, CA)
or iQ™ Supermix (Bio-Rad) and CFX384 Touch™ Real-Time PCR Detection
System C1000 Touch (Bio-Rad). The following TaqMan® probes were used
to measure the EPHA3 expression in hTERT-RPE1 cells: EPHA3
Hs00739096_m1 and RPL19 Hs02338565_gH (Applied Biosystems by Life
Technologies/Thermo Fisher Scientific Inc.). q-PCR primers were designed to
flank exon-exon boundaries and to give specific amplification. Following 3
minutes denaturation at 95°C, 40 cycles of 15 seconds at 95°C and 1 minute
in 60°C were run. A melting curve ranging from 57°C to 95°C was included
in every analysis to confirm the specific amplification. Primer details are listed
in supplementary material Table S1. An exponential expression (ΔCq
Expression) was obtained with formula ΔCq Expression=2–ΔCq, where
ΔCq=Cq (target) – Cq (reference). The average of the ΔCq expression values
of the specific genotypes and time points were visualized with heatmaps
generated using an R statistical programing language heatmap function from
the Heatplus Bioconductor package. We used R version 2.15.3 freely available
at http://www.r-project.org/.
Whole-mount immunohistochemistry and optical tomography
scanning
Sample processing and whole-mount immunohistochemistry of dissected
embryonic lungs at E11.5-E15.5 were performed as described previously
(Alanentalo et al., 2007). Briefly, fixed lungs were dehydrated with methanol
followed by rehydration and processing to immunohistochemical staining.
Localization of anti-E-cadherin (Cell Signaling Technology) was detected
either by fluorescently labeled secondary antibody conjugated to Alexa-
Fluor-594-conjugated anti-rabbit IgG (Life Technologies/Thermo Fisher
Scientific Inc.) or visualized by using the chromogenic DAB substrate
(Immunologic, Duiven, The Netherlands) following the incubation with
poly-HRP-conjugated anti-rabbit IgG antibody (Immunologic, Duiven, The
Netherlands). Fluorescently labeled lungs were processed for OPT scanning
as described previously (Alanentalo et al., 2007), using a Bioptonics OPT
3001M Scanner. Three-dimensional (3D) visualization and branch end-point
analysis was performed with Imaris 3D and 4D data software, using the
Filament analysis function (Bitplane AG, Switzerland). Chromogenically
stained samples were imaged using a Leica MZFLIII stereomicroscope
(Leica, Germany) and Colorview camera (Software imaging system,
Olympus, Japan).
Cell culture and transfections
hTERT-RPE1 cells (Clontech, CA) were maintained in DMEM with 
F-12 (Sigma) containing 10% FBS, 2 mM L-glutamine, 0.348% 
sodium bicarbonate and penicillin-streptomycin (all Gibco by Life
Technologies/Thermo Fisher Scientific Inc.), following the manufacturer’s
recommendations. For gene knockdown, hTERT-RPE1 cells were treated
with 50 nM pooled siRNAs against EPHA3 (GE Dharmacon, Denver, CO)
or siCONTROL non-targeting siRNA #3 (SiCtrl; GE Dharmacon, Denver,
CO) after transfection with Oligofectamine reagent (Invitrogen/Thermo
Fisher Scientific Inc.) on 15-cm culture dishes. One fifth of the transfected
cells was pelleted for RNA extraction and EPHA3 mRNA quantification.
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